ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF LORNOXICAM AND THIOCOLCHICOSIDE IN BULK FORM AND MARKETED PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC

A simple, reproducible, and efficient reverse phase high performance liquid chromatographic method was developed for simultaneous determination of Lornoxicam and Thiocolchicoside in pure form and marketed combined pharmaceutical dosage forms. A column having Symmetry (C18) (150mm × 4.6mm, 5µm) in isocratic mode with mobile phase containing Methanol: Phosphate Buffer (pH-3.8) (28:72 v/v) was used. The flow rate was 1.0 ml/min, and the effluent was monitored at 252 nm. The retention time (min) and linearity range (ppm) for Lornoxicam and Thiocolchicoside were (1.794, 3.440 min) and (10-30, 10-50), respectively. The method has been validated for linearity, accuracy, and precision, robustness, and limit of detection, and limit of quantitation. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.86µg/ml and 2.58µg/ml for Lornoxicam and 1.28µg/ml 3.84µg/ml for Thiocolchicoside respectively. The developed method was found to be accurate, precise and selective for simultaneous determination of Lornoxicam and Thiocolchicoside in tablets.